Sanofi filings document a foreign biopharmaceutical issuer whose American depositary shares represent interests in ordinary shares. Its SEC record includes Form 6-K reports and Form 20-F annual reporting that incorporate parent-company press releases, financial reports, governance materials and ADR-related disclosure.
Sanofi’s filings cover operating results, research and development spending, product and pipeline updates, regulatory approvals and designations, and therapeutic areas such as immunology, vaccines, rare diseases, oncology, respiratory disease and diabetes. They also document bond issuance under its Euro Medium Term Note programme, share buyback activity, annual meeting resolutions, board and executive appointments, risk factors and capital-structure matters.
Sanofi filed a Form 13F reporting institutional holdings managed by its investment unit. The submission lists 9 information-table entries with a reported aggregate value of $335,959,156. The report is signed by Alexandra Roger and indicates 0 other included managers.
Sanofi held its Mixed General Meeting of Shareholders on April 29, 2026, where all resolutions were approved with strong support. Shareholders appointed Belén Garijo to the Board and confirmed that, in line with a prior Board decision, she will assume the role of Chief Executive Officer on May 1, 2026.
The meeting approved the social and consolidated accounts for fiscal year 2025 and decided on an ordinary annual dividend of €4.12 per share, with payment on May 7, 2026. The Board renewed mandates for Christophe Babule and Jean-Paul Kress and appointed Christel Heydemann, CEO of Orange, as an independent director, strengthening digital and AI expertise. Sanofi’s Board now has 16 members and a high level of independence and gender diversity.
Sanofi has successfully priced an offering of €2.3 billion of notes, issued in three tranches under its Euro Medium Term Note programme. This debt financing provides the company with additional funding through the bond market.
Sanofi intends to use the net proceeds from the notes for general corporate purposes, giving it flexibility to support its operations, investments, or balance sheet needs as management decides over time.
Sanofi used this report to bundle several April 2026 drug and vaccine milestones. Its protein-based COVID-19 vaccine Nuvaxovid showed statistically significantly lower systemic and local side effects than Moderna’s mNEXSPIKE in a 1,000‑adult head‑to‑head trial, which also found fewer severe symptoms and better patient willingness to be revaccinated.
The FDA extended the review of subcutaneous Sarclisa for multiple myeloma to July 23, 2026, while Europe’s CHMP recommended approval of this on‑body injector and manual formulation. The FDA also approved Tzield to delay stage 3 type 1 diabetes in children as young as one year, and cleared Dupixent as the first biologic for U.S. children aged two to 11 with uncontrolled chronic spontaneous urticaria.
In neurology, CHMP issued a positive opinion for Cenrifki (tolebrutinib) to treat non‑relapsing secondary progressive multiple sclerosis, based on phase 3 data, with liver enzyme monitoring highlighted due to drug‑induced liver injury risk.
Sanofi reported Q1 2026 net sales of €10,509 million, up 13.6% at constant exchange rates, with business EPS rising to €1.88, an increase of 14.0% at CER. Growth was driven by pharma launches, Dupixent, and recent acquisitions.
Pharma launch sales climbed 49.6% at CER to €1.2 billion, while Dupixent sales rose 30.8% to €4.17 billion. Vaccines sales reached €1.29 billion, up 2.1% at CER, supported by newly acquired Heplisav‑B and Beyfortus. Business operating income grew 10.9% at CER to €2.97 billion, despite higher Regeneron profit sharing.
The company completed the $2.2 billion Dynavax acquisition and executed €921 million of a planned €1 billion share buyback, while net debt increased to €12.9 billion. Sanofi affirmed 2026 guidance for high single‑digit sales growth at CER, with business EPS expected to grow slightly faster than sales.
Sanofi reports two major immunology updates. Its experimental drug lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in moderate-to-severe asthma (AIRCULES) and chronic rhinosinusitis with nasal polyps (DUET), showing fewer exacerbations and better lung function or polyp scores versus placebo, with a generally acceptable safety profile. A separate phase 2b atopic dermatitis study (VELVET) missed its primary endpoint but improved key skin-clearance measures. Lunsekimig is progressing into new phase 2 and phase 3 programs in high-risk asthma.
Sanofi also announces that the European Commission approved Dupixent for moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years who do not respond adequately to antihistamines and are naïve to anti-IgE therapy. This expands Dupixent’s prior EU approval in CSU for adults and adolescents, based on the LIBERTY-CUPID phase 3 program, where Dupixent reduced itch and hives and improved disease control with a safety profile consistent with earlier dermatology uses.
SANOFI reported a Schedule 13G/A showing Amundi and Amundi Asset Management beneficially own 61,506,935 shares, representing 5.04% of the class.
The filing states Amundi holds shared voting power for 30,913,607 shares and shared dispositive power for 61,506,935. It notes 27,407,379 shares are held in an employee FCPE whose voting rights are exercised by the FCPE supervisory board.
Sanofi files a Form 6-K highlighting multiple March 2026 R&D and regulatory milestones across immunology and oncology. Dupixent won approval in Japan as the first targeted medicine for adults with moderate-to-severe bullous pemphigoid, based on the LIBERTY‑BP‑ADEPT phase 2/3 study where 18% of treated patients achieved sustained disease remission versus 4% on placebo at Week 36.
The European regulator’s CHMP issued a positive opinion for a subcutaneous Sarclisa formulation delivered by on-body injector for multiple myeloma, supported by the phase 3 IRAKLIA study and other trials. Sanofi also reported positive phase 3 results for amlitelimab in three large atopic dermatitis studies (COAST 1, COAST 2 and SHORE), showing improved skin clearance and symptom relief with both every-four-week and every-12-week dosing.
Additionally, the European Commission granted conditional marketing authorisation for Rezurock to treat chronic graft-versus-host disease in patients aged 12 and older when prior systemic therapies are inadequate. This decision drew on phase 2 ROCKstar data, where Rezurock delivered a 74% best overall response rate, and supports Sanofi’s expansion in serious immune-mediated diseases.
Sanofi reports that the US FDA has granted Breakthrough Therapy designation to venglustat, an investigational oral glucosylceramide synthase inhibitor, for treating neurological manifestations of type 3 Gaucher disease, a rare lysosomal storage disorder.
The designation is based on the phase 3 LEAP2MONO study, where patients on venglustat showed statistically significant neurological improvement versus those on imiglucerase enzyme replacement therapy (p=0.007). Venglustat was generally well tolerated; the most common adverse events included headache, nausea, spleen enlargement and diarrhea, with comparable or acceptable rates versus the comparator arm.
There are currently no approved treatments for the neurological symptoms of GD3, and venglustat is designed to cross the blood-brain barrier to address underlying central nervous system pathology. Sanofi plans to pursue global regulatory filings for venglustat in GD3 during 2026.
Sanofi filed a Form 6-K summarizing three March 2026 updates. Japan’s Ministry of Health, Labour and Welfare granted orphan drug designation to rilzabrutinib, an oral BTK inhibitor, for IgG4-related disease after phase 2 data showed reduced disease flares, improved markers and lower glucocorticoid use, with a safety profile consistent with earlier studies. Rilzabrutinib is approved for immune thrombocytopenia in the US, EU and UAE and is in a phase 3 IgG4-RD study. Sanofi also filed an amendment to its French “Document d’Enregistrement Universel” containing the Annual Financial Report, adding corporate governance information. The Board will ask shareholders on April 29, 2026 to appoint Christel Heydemann as an independent director, renew the mandates of Christophe Babule and Jean‑Paul Kress, and notes that Patrick Kron will leave the Board, which would remain at 16 members and 57% women excluding employee representatives.